Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome [ID1405]
In development [GID-TA10305] Expected publication date: 31 March 2021
Search results
642 results
-
-
Esketamine for treatment-resistant depression (ID1414)
In development [GID-TA10371] Expected publication date: TBC
-
Brolucizumab for treating wet age-related macular degeneration [ID1254]
In development [GID-TA10455] Expected publication date: 03 February 2021
-
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs only have failed (partial review of TA375) [ID2710]
In development [GID-TA10586] Expected publication date: TBC
-
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 1 prior therapy [ID1557]
In development [GID-TA10485] Expected publication date: 23 June 2021
-
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency [ID3802]
In development [GID-TA10670] Expected publication date: TBC
-
AR101 for treating peanut allergy [ID1282]
In development [GID-TA10713] Expected publication date: TBC
-
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID1680]
In development [GID-TA10551] Expected publication date: 10 February 2021
-
Pegcetacoplan for previously treated paroxysmal nocturnal haemoglobinuria [ID3746]
In development [GID-TA10651] Expected publication date: 02 February 2022
-
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer (CDF Review of TA557) [ID1584]
In development [GID-TA10529] Expected publication date: 10 March 2021
-
Pembrolizumab for advanced, unresectable or metastatic urothelial cancer (CDF review of TA522) [ID1634]
In development [GID-TA10710] Expected publication date: TBC
-
Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma [ID1313]
In development [GID-TA10312] Expected publication date: 24 February 2021
-
Relugolix with oestradiol and norethindrone acetate for heavy menstrual bleeding associated with uterine fibroids [ID3842]
In development [GID-TA10734] Expected publication date: TBC
-
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]
In development [GID-HST10004] Expected publication date: TBC
-
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
In development [GID-HST10007] Expected publication date: TBC
-
Workplace health for employees with disabilities and long-term conditions
In development [GID-PHG58] Expected publication date: TBC
-
Workplace health - older employees
In development [GID-PHG59] Expected publication date: 24 March 2016
-
Personal, social, health and economic education focusing on sex and relationships and alcohol education
In development [GID-PHG0] Expected publication date: TBC
-
Housing: planning to improve health and wellbeing
In development [GID-NG10053] Expected publication date: TBC
-
Assessment, referral and management of Adrenal dysfunction
In development [GID-NG10052] Expected publication date: TBC
-
Diagnostic services
In development [GID-CGWAVE0773] Expected publication date: TBC
-
Reducing the mortality and morbidity for healthcare associated infections
In development [GID-NG10059] Expected publication date: TBC
-
Hernia
In development [GID-CGWAVE0771] Expected publication date: TBC
-
Cutting blocks for total knee arthroplasty
In development [GID-IP1112] Expected publication date: TBC
-
Implantable Vagus Nerve Stimulator in Heart Failure
In development [GID-IP1145] Expected publication date: TBC
-
Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis
In development [GID-IP1151] Expected publication date: TBC
-
Extra corporeal membrane oxygenation for acute heart failure in children
In development [GID-IP1153] Expected publication date: TBC
-
Degradable surgical implant
In development [GID-IP1197] Expected publication date: TBC
-
MRI guided focussed ultrasound for chronic pain
In development [GID-IP1043] Expected publication date: TBC
-
Ex utero intrapartum therapy for fetal obstruction
In development [GID-IP1156] Expected publication date: TBC
-
Peroral endoscopic myotomy (POEM) for achalasia
In development [GID-IP1229] Expected publication date: TBC
-
Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children
In development [GID-IP1170] Expected publication date: TBC
-
Intravaginal sling for stress urinary incontinence
In development [GID-IP267] Expected publication date: TBC
-
Electrochemotherapy for the treatment of malignant melanoma
In development [GID-IP1041] Expected publication date: TBC
-
Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169
In development [GID-TA10324] Expected publication date: TBC
-
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer ID1335
In development [GID-TA10315] Expected publication date: TBC
-
Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies ID1455
In development [GID-TA10356] Expected publication date: TBC
-
Prostate cancer (prevention) - dutasteride [ID75]
In development [GID-TAG409] Expected publication date: TBC
-
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]
In development [GID-TAG411] Expected publication date: TBC
-
Obesity - lorcaserin [ID337]
In development [GID-TAG420] Expected publication date: TBC
-
Dementia (non-Alzheimer) - new pharmaceutical treatments [ID380]
In development [GID-TAG369] Expected publication date: TBC
-
Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]
In development [GID-TAG432] Expected publication date: TBC
-
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
In development [GID-TAG403] Expected publication date: TBC
-
Obesity - phentermine (with topiramate) [ID543]
In development [GID-TAG439] Expected publication date: TBC
-
Osteoarthritis and rheumatoid arthritis - cox-II inhibitors (review) [ID388]
In development [GID-TAG372] Expected publication date: TBC
-
Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]
In development [GID-TAG423] Expected publication date: TBC
-
Prostate cancer - intensity modulated radiotherapy [ID17]
In development [GID-TAG396] Expected publication date: TBC
-
Colon cancer (adjuvant) - irinotecan [ID379]
In development [GID-TAG380] Expected publication date: TBC
-
Head and neck cancer - contusugene ladenovec [ID76]
In development [GID-TAG407] Expected publication date: TBC
-
Lung cancer (non-small cell) - afatinib [ID357]
In development [GID-TAG422] Expected publication date: TBC